{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T01:49:07Z","timestamp":1778636947873,"version":"3.51.4"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.bcp.2021.114612","type":"journal-article","created":{"date-parts":[[2021,5,16]],"date-time":"2021-05-16T17:39:37Z","timestamp":1621186777000},"page":"114612","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Acyclovir induces fetal hemoglobin via downregulation of \u03b3-globin repressors, BCL11A and SOX6 trans-acting factors"],"prefix":"10.1016","volume":"190","author":[{"given":"Hamad","family":"Ali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faisal","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed","family":"Ghulam Musharraf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9813","key":"10.1016\/j.bcp.2021.114612_b0005","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0140-6736(11)60283-3","article-title":"Thalassaemia","volume":"379","author":"Higgs","year":"2012","journal-title":"The Lancet"},{"issue":"6","key":"10.1016\/j.bcp.2021.114612_b0010","doi-asserted-by":"crossref","first-page":"480","DOI":"10.2471\/BLT.06.036673","article-title":"Global Epidemiology of Haemoglobin Disorders and Derived Service Indicators","volume":"2008","author":"Modell","year":"2008","journal-title":"Bull. World Health Organ."},{"issue":"13","key":"10.1016\/j.bcp.2021.114612_b0015","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1182\/blood-2010-08-300335","article-title":"How I Treat Thalassemia","volume":"118","author":"Rachmilewitz","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bcp.2021.114612_b0020","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1365-2141.1995.tb05288.x","article-title":"Novel Treatment Options in the Severe \u0392-Globin Disorders","volume":"91","author":"Rodgers","year":"1995","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.bcp.2021.114612_b0025","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0268-960X(94)90109-0","article-title":"Fetal Hemoglobin Levels in Adults","volume":"8","author":"Rochette","year":"1994","journal-title":"Blood Rev."},{"issue":"3","key":"10.1016\/j.bcp.2021.114612_b0030","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1034\/j.1600-0609.2003.00113.x","article-title":"Accumulation of \u0393-Globin mRNA in Human Erythroid Cells Treated with Angelicin","volume":"71","author":"Lampronti","year":"2003","journal-title":"Eur. J. Haematol."},{"issue":"1 COOLEY'S ANEM","key":"10.1016\/j.bcp.2021.114612_b0035","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1749-6632.1998.tb10467.x","article-title":"Elimination of Transfusions through Induction of Fetal Hemoglobin Synthesis in Cooley's Anemia","volume":"850","author":"Olivieri","year":"1998","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"6","key":"10.1016\/j.bcp.2021.114612_b0040","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/sj.tpj.6500433","article-title":"Fetal Hemoglobin in Sickle Cell Anemia: Genetic Determinants of Response to Hydroxyurea","volume":"7","author":"Ma","year":"2007","journal-title":"Pharmacogenomics J"},{"issue":"5","key":"10.1016\/j.bcp.2021.114612_b0045","first-page":"339","article-title":"Fetal Globin Stimulant Therapies in the Beta-Hemoglobinopathies: Principles and Current Potential","volume":"37","author":"Perrine","year":"2008","journal-title":"Pediatr. Ann."},{"issue":"1","key":"10.1016\/j.bcp.2021.114612_b0050","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1002\/ajh.24590","article-title":"Effects of Hydroxyurea on F-Cells in Sickle Cell Disease and Potential Impact of a Second Fetal Globin Inducer","volume":"92","author":"Dai","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcp.2021.114612_b0055","doi-asserted-by":"crossref","unstructured":"C.T. Quinn, O. Niss, A. Pfeiffer, J. Korpik, H. Bonar, M. Reynaud, R.E. Ware, P.T. McGann, Pharmacokinetics-Guided Dosing of Hydroxyurea Can Achieve near-Pancellular Fetal Hemoglobin Expression in Sickle Cell Anemia: F-Cell Analysis as a Benchmark for Disease-Modifying Therapy. 2019, American Society of Hematology Washington, DC.","DOI":"10.1182\/blood-2019-130414"},{"issue":"1","key":"10.1016\/j.bcp.2021.114612_b0060","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1182\/blood.V69.1.109.109","article-title":"Hydroxyurea-Induced Augmentation of Fetal Hemoglobin Production In","volume":"69","author":"Charache","year":"1987","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bcp.2021.114612_b0065","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12288-013-0261-4","article-title":"Hydroxyurea in Sickle Cell Disease: Drug Review","volume":"30","author":"Agrawal","year":"2014","journal-title":"Indian Journal of Hematology and Blood Transfusion"},{"issue":"8","key":"10.1016\/j.bcp.2021.114612_b0070","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1179\/1607845414Y.0000000222","article-title":"Meta-Analysis on Effectiveness of Hydroxyurea to Treat Transfusion-Dependent Beta-Thalassemia","volume":"20","author":"Bayanzay","year":"2015","journal-title":"Hematology"},{"issue":"S1","key":"10.1016\/j.bcp.2021.114612_b0075","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jmv.1890410503","article-title":"Acyclovir: Discovery, Mechanism of Action, and Selectivity","volume":"41","author":"Elion","year":"1993","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.bcp.2021.114612_b0080","unstructured":"R.H. DeBellis, B.F. Erlanger, Methods of Treating Sickle Cell Disease. 2005, Google Patents."},{"issue":"10","key":"10.1016\/j.bcp.2021.114612_b0085","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/ng2108","article-title":"A Qtl Influencing F Cell Production Maps to a Gene Encoding a Zinc-Finger Protein on Chromosome 2p15","volume":"39","author":"Menzel","year":"2007","journal-title":"Nat. Genet."},{"issue":"5909","key":"10.1016\/j.bcp.2021.114612_b0090","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1126\/science.1165409","article-title":"Human Fetal Hemoglobin Expression Is Regulated by the Developmental Stage-Specific Repressor Bcl11a","volume":"322","author":"Sankaran","year":"2008","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.bcp.2021.114612_b0095","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1101\/gad.1897310","article-title":"Transcriptional Silencing of \u0393-Globin by Bcl11a Involves Long-Range Interactions and Cooperation with Sox6","volume":"24","author":"Xu","year":"2010","journal-title":"Genes Dev."},{"issue":"20","key":"10.1016\/j.bcp.2021.114612_b0100","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1182\/blood-2010-03-274399","article-title":"Fetal Globin Expression Is Regulated by Friend of Prmt1","volume":"116","author":"van Dijk","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bcp.2021.114612_b0105","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2002-02-0387","article-title":"X-Linked Thrombocytopenia with Thalassemia from a Mutation in the Amino Finger of Gata-1 Affecting DNA Binding Rather Than Fog-1 Interaction","volume":"100","author":"Yu","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcp.2021.114612_b0110","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40169-016-0092-7","article-title":"Hydroxyurea Down-Regulates Bcl11a, Klf-1 and Myb through Mirna-Mediated Actions to Induce \u03b3-Globin Expression: Implications for New Therapeutic Approaches of Sickle Cell Disease","volume":"5","author":"Pule","year":"2016","journal-title":"Clinical and Translational Medicine"},{"issue":"9","key":"10.1016\/j.bcp.2021.114612_b0115","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/ng.630","article-title":"Haploinsufficiency for the Erythroid Transcription Factor Klf1 Causes Hereditary Persistence of Fetal Hemoglobin","volume":"42","author":"Borg","year":"2010","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bcp.2021.114612_b0120","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejphar.2019.05.027","article-title":"Thiourea Derivatives Induce Fetal Hemoglobin Production in-Vitro: A New Class of Potential Therapeutic Agents for \u0392-Thalassemia","volume":"855","author":"Ali","year":"2019","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2021.114612_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2020.112168","article-title":"Tenofovir Disoproxil Fumarate Induces Fetal Hemoglobin Production in K562 Cells and \u0392-Yac Transgenic Mice: A Therapeutic Approach for \u0393-Globin Induction","volume":"394","author":"Khan","year":"2020","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.bcp.2021.114612_b0130","doi-asserted-by":"crossref","unstructured":"J. O'brien, I. Wilson, T. Orton, F. Pognan, Investigation of the Alamar Blue (Resazurin) Fluorescent Dye for the Assessment of Mammalian Cell Cytotoxicity. The FEBS Journal, 2000. 267(17): p. 5421-5426.","DOI":"10.1046\/j.1432-1327.2000.01606.x"},{"issue":"2","key":"10.1016\/j.bcp.2021.114612_b0135","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.bcmd.2007.07.006","article-title":"Erythroid Differentiation and Maturation from Peripheral Cd34+ Cells in Liquid Culture: Cellular and Molecular Characterization","volume":"40","author":"Ronzoni","year":"2008","journal-title":"Blood Cells Mol. Dis."},{"issue":"4","key":"10.1016\/j.bcp.2021.114612_b0140","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of Relative Gene Expression Data Using Real-Time Quantitative Pcr and the 2\u2212 \u0394\u03b4ct Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"issue":"2","key":"10.1016\/j.bcp.2021.114612_b0145","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A Simple Practice Guide for Dose Conversion between Animals and Human","volume":"7","author":"Nair","year":"2016","journal-title":"Journal of basic and clinical pharmacy"},{"issue":"8","key":"10.1016\/j.bcp.2021.114612_b0150","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1590\/S0100-879X1997000800004","article-title":"Minimal Doses of Hydroxyurea for Sickle Cell Disease","volume":"30","author":"Lima","year":"1997","journal-title":"Braz. J. Med. Biol. Res."},{"issue":"7","key":"10.1016\/j.bcp.2021.114612_b0155","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood-2004-12-4973","article-title":"Long-Term Hydroxyurea Therapy for Infants with Sickle Cell Anemia: The Husoft Extension Study","volume":"106","author":"Hankins","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2021.114612_b0160","article-title":"Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation","volume":"110","author":"Amend","year":"2016","journal-title":"JoVE (Journal of Visualized Experiments)"},{"issue":"1","key":"10.1016\/j.bcp.2021.114612_b0165","first-page":"32","article-title":"Inducers of Erythroid Differentiation in K562 Human Leukemia Cells","volume":"9","author":"Rowley","year":"1981","journal-title":"Exp. Hematol."},{"issue":"4","key":"10.1016\/j.bcp.2021.114612_b0170","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1182\/blood.V65.4.862.862","article-title":"K562 Human Erythroleukemia Cells Demonstrate Commitment","volume":"65","author":"Rowley","year":"1985","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bcp.2021.114612_b0175","first-page":"481","article-title":"Involvement of P38 Kinase in Hydroxyurea-Induced Differentiation of K562 Cells","volume":"12","author":"Park","year":"2001","journal-title":"Cell Growth Differ."},{"issue":"1","key":"10.1016\/j.bcp.2021.114612_b0180","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0006-2952(00)00297-5","article-title":"Induction of Erythroid Differentiation of Human K562 Cells by Cisplatin Analogs","volume":"60","author":"Bianchi","year":"2000","journal-title":"Biochem. Pharmacol."},{"issue":"8","key":"10.1016\/j.bcp.2021.114612_b0185","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1101\/gad.1897310","article-title":"Transcriptional Silencing of {Gamma}-Globin by Bcl11a Involves Long-Range Interactions and Cooperation with Sox6","volume":"24","author":"Xu","year":"2010","journal-title":"Genes Dev"},{"issue":"3","key":"10.1016\/j.bcp.2021.114612_b0190","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/BF03401554","article-title":"Hemoglobin Switching in Humans Is Accompanied by Changes in the Ratio of the Transcription Factors, Gata-1 and Sp1","volume":"1","author":"Bacon","year":"1995","journal-title":"Mol. Med."},{"key":"10.1016\/j.bcp.2021.114612_b0195","doi-asserted-by":"crossref","unstructured":"B.t. Ch\u00e9nais, Requirement of Gata-1 and P45 Nf-E2 Expression in Butyric Acid-Induced Erythroid Differentiation. Biochemical and Biophysical Research Communications, 1998. 253(3): p. 883-886.","DOI":"10.1006\/bbrc.1998.9869"},{"issue":"2","key":"10.1016\/j.bcp.2021.114612_b0200","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2174\/092986707779313318","article-title":"Medicinal Chemistry of Fetal Hemoglobin Inducers for Treatment of \u0392-Thalassemia","volume":"14","author":"Gambari","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bcp.2021.114612_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcmd.2019.102345","article-title":"Conjugate Prodrug an-233 Induces Fetal Hemoglobin Expression in Sickle Erythroid Progenitors and \u0392-Yac Transgenic Mice","volume":"79","author":"Oseghale","year":"2019","journal-title":"Blood Cells Mol. Dis."},{"issue":"12","key":"10.1016\/j.bcp.2021.114612_b0210","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1182\/blood.V84.12.4344.bloodjournal84124344","article-title":"Alpha-Amino Butyric Acid Cannot Reactivate the Silenced Gamma Gene of the Beta Locus Yac Transgenic Mouse","volume":"84","author":"Pace","year":"1994","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bcp.2021.114612_b0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0144660","article-title":"Novel Inducers of Fetal Globin Identified through High Throughput Screening (Hts) Are Active in Vivo in Anemic Baboons and Transgenic Mice","volume":"10","author":"Boosalis","year":"2015","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.bcp.2021.114612_b0220","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/ajmg.1320270305","article-title":"The Relationship between Fetal Hemoglobin and Disease Severity in Children with Sickle Cell Anemia","volume":"27","author":"Odenheimer","year":"1987","journal-title":"Am. J. Med. Genet."},{"issue":"7","key":"10.1016\/j.bcp.2021.114612_b0225","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/dvdy.20802","article-title":"Understanding Mechanisms of \u0393-Globin Gene Regulation to Develop Strategies for Pharmacological Fetal Hemoglobin Induction","volume":"235","author":"Pace","year":"2006","journal-title":"Dev. Dyn."},{"issue":"12","key":"10.1016\/j.bcp.2021.114612_b0230","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2003-05-1738","article-title":"Effects of 5-Aza-2\u2032-Deoxycytidine on Fetal Hemoglobin Levels, Red Cell Adhesion, and Hematopoietic Differentiation in Patients with Sickle Cell Disease","volume":"102","author":"Saunthararajah","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bcp.2021.114612_b0235","first-page":"47","article-title":"Evaluation of Novel Fetal Hemoglobin Inducer Drugs in Treatment of \u0392-Hemoglobinopathy Disorders","volume":"7","author":"Fard","year":"2013","journal-title":"International Journal of Hematology-Oncology and Stem Cell Research"},{"issue":"1","key":"10.1016\/j.bcp.2021.114612_b0240","first-page":"58","article-title":"Induction of Fetal Hemoglobin in the Treatment of Sickle Cell Disease","volume":"2006","author":"Fathallah","year":"2006","journal-title":"ASH Education Program Book"},{"issue":"3","key":"10.1016\/j.bcp.2021.114612_b0245","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/blood.V45.3.321.321","article-title":"Human Chronic Myelogenous Leukemia Cell-Line with Positive Philadelphia Chromosome","volume":"45","author":"Lozzio","year":"1975","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bcp.2021.114612_b0250","first-page":"123","article-title":"The Human Erythroleukemia K562 Cell Culture System for Identification of Inducers of Fetal Hemoglobin","volume":"15","author":"Gambari","year":"2003","journal-title":"Minerva Biotecnologica"},{"issue":"6","key":"10.1016\/j.bcp.2021.114612_b0255","first-page":"1790","article-title":"Sustained Induction of Fetal Hemoglobin by Pulse Butyrate Therapy in Sickle Cell Disease","volume":"93","author":"Atweh","year":"1999","journal-title":"Blood, The Journal of the American Society of Hematology"},{"key":"10.1016\/j.bcp.2021.114612_b0260","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.gde.2015.08.001","article-title":"Hemoglobin Switching's Surprise: The Versatile Transcription Factor Bcl11a Is a Master Repressor of Fetal Hemoglobin","volume":"33","author":"Bauer","year":"2015","journal-title":"Curr Opin Genet Dev"},{"issue":"9","key":"10.1016\/j.bcp.2021.114612_b0265","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/ng.637","article-title":"Klf1 Regulates Bcl11a Expression and Gamma- to Beta-Globin Gene Switching","volume":"42","author":"Zhou","year":"2010","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.bcp.2021.114612_b0270","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0092-8674(00)80318-9","article-title":"Fog, a Multitype Zinc Finger Protein, Acts as a Cofactor for Transcription Factor Gata-1 in Erythroid and Megakaryocytic Differentiation","volume":"90","author":"Tsang","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2021.114612_b0275","doi-asserted-by":"crossref","unstructured":"K.R. Peterson, C.H. Clegg, C. Huxley, B.M. Josephson, H.S. Haugen, T. Furukawa, G. Stamatoyannopoulos, Transgenic Mice Containing a 248-Kb Yeast Artificial Chromosome Carrying the Human Beta-Globin Locus Display Proper Developmental Control of Human Globin Genes. Proceedings of the National Academy of Sciences, 1993. 90(16): p. 7593-7597.","DOI":"10.1073\/pnas.90.16.7593"},{"key":"10.1016\/j.bcp.2021.114612_b0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/507894","article-title":"Induction of Fetal Hemoglobin in Vivo Mediated by a Synthetic \u0393-Globin Zinc Finger Activator","volume":"2012","author":"Costa","year":"2012","journal-title":"Anemia"},{"key":"10.1016\/j.bcp.2021.114612_b0285","doi-asserted-by":"crossref","unstructured":"K.R. Peterson, Q.L. Li, C.H. Clegg, T. Furukawa, P.A. Navas, E.J. Norton, T.G. Kimbrough, G. Stamatoyannopoulos, Use of Yeast Artificial Chromosomes (Yacs) in Studies of Mammalian Development: Production of Beta-Globin Locus Yac Mice Carrying Human Globin Developmental Mutants. Proceedings of the National Academy of Sciences, 1995. 92(12): p. 5655-5659.","DOI":"10.1073\/pnas.92.12.5655"},{"issue":"3","key":"10.1016\/j.bcp.2021.114612_b0290","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nm.3101","article-title":"Lysine-Specific Demethylase 1 Is a Therapeutic Target for Fetal Hemoglobin Induction","volume":"19","author":"Shi","year":"2013","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.bcp.2021.114612_b0295","first-page":"229","article-title":"Fetal Hemoglobin Induction by the Histone Deacetylase Inhibitor, Scriptaid","volume":"51","author":"Johnson","year":"2005","journal-title":"Cellular and Molecular Biology (Noisy-le-Grand, France)"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221002185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221002185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:26:21Z","timestamp":1757769981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295221002185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":59,"alternative-id":["S0006295221002185"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114612","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acyclovir induces fetal hemoglobin via downregulation of \u03b3-globin repressors, BCL11A and SOX6 trans-acting factors","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114612","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114612"}}